KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Hims & Hers Health (HIMS) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Hims & Hers Health (HIMS) over the last 7 years, with Q3 2025 value amounting to $345.8 million.

  • Hims & Hers Health's Cash & Equivalents rose 10890.66% to $345.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $345.8 million, marking a year-over-year increase of 10890.66%. This contributed to the annual value of $220.6 million for FY2024, which is 12819.9% up from last year.
  • According to the latest figures from Q3 2025, Hims & Hers Health's Cash & Equivalents is $345.8 million, which was up 10890.66% from $1.1 billion recorded in Q2 2025.
  • Over the past 5 years, Hims & Hers Health's Cash & Equivalents peaked at $1.1 billion during Q2 2025, and registered a low of $46.8 million during Q4 2022.
  • In the last 5 years, Hims & Hers Health's Cash & Equivalents had a median value of $88.2 million in 2021 and averaged $167.0 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 763313.07% in 2021, then tumbled by 4863.69% in 2022.
  • Hims & Hers Health's Cash & Equivalents (Quarter) stood at $71.8 million in 2021, then plummeted by 34.84% to $46.8 million in 2022, then surged by 106.67% to $96.7 million in 2023, then soared by 128.2% to $220.6 million in 2024, then surged by 56.76% to $345.8 million in 2025.
  • Its Cash & Equivalents stands at $345.8 million for Q3 2025, versus $1.1 billion for Q2 2025 and $273.7 million for Q1 2025.